# A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)

> **NCT06215755** · PHASE1 · TERMINATED · sponsor: **Verge Genomics** · enrollment: 54 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** VRG50635

## Key facts

- **NCT ID:** NCT06215755
- **Lead sponsor:** Verge Genomics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-15
- **Primary completion:** 2025-07-07
- **Final completion:** 2025-07-07
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Study terminated by Sponsor due to lack of risk-benefit data.
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06215755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06215755, "A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06215755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*